Antibody Information
General Information of This Antibody
| Antibody ID | ANI0BYCUP |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | Murine mAb B3 |
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Murine IgG |
|||||
| Antigen Name | Poly [ADP-ribose] polymerase 1 (PARP1) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
LMB-7 [Phase 1]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Key disease criteria include histologically confirmed CNS/extraneural tumors with ≥30% B3 antibody reactivity in CSF/tumor cells. Patient requirements: age ≥18, Karnofsky 50-100%, adequate hematologic/renal/hepatic function
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT00003020 | Clinical Status | PHASE1 | ||
| Clinical Description |
Protocol for a Phase I Study of Intrathecal LMB-7 (Single-Chain Immunotoxin Constructed From Monoclonal Antibody B3-Pseudomonas Exotoxin PE 38) [IND 5863, NSC 658931] in the Treatment of Patients With Leptomeningeal Neoplasms
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Patients Enrolled |
Patients with leptomeningeal metastases.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT00003020 | Clinical Status | Phase 1 | ||
| Clinical Description |
Phase 1 dose-escalation study of intravenous CMD-193 in subjects with advanced malignant solid tumors.
|
||||
References